Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Last trade$2.99
Day change-$0.385 (-11.41%)
Day range$2.96 – $3.50
Volume361,697
Market cap$70M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$69.65M
Price / earnings
—
Price / book
0.82×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.33×
Profitability
Earnings per share
-$5.64
Return on assets
-94.64%
Return on equity
-137.23%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.4×
Quick ratio
3.4×
Cash ratio
0.86×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$92.39M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CRBP, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.58M
$5.02M
$4.49M
$3.56M
$3.56M
$3.97M
$4.13M
$3.82M
Research and development
$34.25M
$31.18M
$19.82M
$18.41M
$20.86M
$15.19M
$15.64M
$8.79M
Total operating expenses
$38.82M
$36.19M
$24.3M
$21.97M
$24.42M
$19.15M
$19.78M
$12.61M
Operating income
-$38.82M
-$36.19M
-$24.3M
-$21.97M
-$24.42M
-$19.15M
-$19.78M
-$12.61M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$37.75M
-$35.04M
-$22.97M
-$20.56M
-$23.34M
-$17.66M
-$16.98M
-$9.53M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$37.75M
-$35.04M
-$22.97M
-$20.56M
-$23.34M
-$17.66M
-$16.98M
-$9.53M
Net income attributable to common shareholders
-$37.75M
-$35.04M
-$22.97M
-$20.56M
-$23.34M
-$17.66M
-$16.98M
-$9.53M
EBITDA
-$38.77M
-$36.14M
-$24.26M
-$21.92M
-$24.37M
-$19.1M
-$19.69M
-$12.47M
Basic earnings per share
-$1.81
-$1.81
-$1.23
-$1.24
-$1.90
-$1.44
-$1.39
-$0.78
Diluted earnings per share
-$1.81
-$1.81
-$1.23
-$1.24
-$1.90
-$1.44
-$1.39
-$0.78
Recent news
Company coverage with links to the original publishers.
Corbus Pharmaceuticals announced that CEO Yuval Cohen will present a corporate overview and participate in investor meetings at the RBC Capital Markets Global Healthcare Conference (May 19-20, 2026) and the Jefferies Global Healthcare Conference (June 2-4, 2026). The clinical-stage company is developing CRB-701, an antibody drug conjugate for Nectin-4-expressing tumors, and CRB-913, an obesity treatment candidate.
Corbus Pharmaceuticals announced FDA alignment on the registration path for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, with a registrational study expected to launch this summer. The company completed enrollment in its CANYON-1 Phase 1b study of CRB-913 for obesity treatment with topline data expected summer 2026. Q1 2026 net loss was $23.0 million with $138.2 million in cash expected to fund operations into 2028.
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage oncology and obesity company, announced that CEO Yuval Cohen will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026. The company's pipeline includes CRB-701 (antibody drug conjugate), CRB-601 (anti-integrin monoclonal antibody), and CRB-913 (CB1 inverse agonist for obesity treatment), which recently demonstrated a favorable safety profile and emerging evidence of weight loss in Phase 1a studies.
Corbus Pharmaceuticals has priced a public offering of 4,744,231 common stock shares and pre-funded warrants, raising approximately $75 million to fund clinical development and corporate purposes.
Corbus Pharmaceuticals plans to raise approximately $75 million through a public offering of 4,744,231 common stock shares and pre-funded warrants, with proceeds intended to fund clinical development and working capital.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.